GlassScriptPhysician profile
Lowell J Kleinman
NPI 1407875941
$889.85
in general payments reported to CMS, 2019-2025
14 companies · $16.56 in 2025
The $16.56 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $203 · 2020: $137 · 2023: $274 · 2024: $259 · 2025: $16.56.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $549.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $549.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $129.11 | 2019-2024 | Mounjaro, Jardiance, Zepbound |
| Novartis Pharmaceuticals Corporation | $123.49 | 2023-2025 | |
| Pfizer INC. | $112.03 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $111.20 | 2019-2023 | Jardiance |
| Glaxosmithkline, LLC. | $87.10 | 2023-2024 | Shingrix, Arexvy |
| Astrazeneca Pharmaceuticals LP | $85.13 | 2023-2024 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $61.37 | 2019-2023 | Ozempic, Rybelsus |
| Amarin Pharma, INC. | $45.19 | 2020 | |
| Merck Sharp & Dohme LLC | $39.27 | 2019-2023 | Belsomra |
| Exact Sciences Corporation | $23.87 | 2023 | Cologuard Collection Kit |
| Gilead Sciences, INC. | $21.74 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $20.41 | 2023 | Xifaxan |
| Astellas Pharma US INC | $15.53 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $14.41 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lowell Kleinman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.